BEDFORD, Mass. --(BUSINESS WIRE)--Nov. 15, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform , today announced its participation in two upcoming
BEDFORD, Mass. --(BUSINESS WIRE)--Nov. 5, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid ("HA") technology platform , today announced plans to showcase its
Total Revenue Increases 11% and Net Income Increases 21% Year-over-Year Company Raises Full Year 2019 Revenue and Earnings Guidance Executing Five-Year Strategic Plan Focused on Joint Preservation and Restoration BEDFORD, Mass. --(BUSINESS WIRE)--Oct. 24, 2019-- Anika Therapeutics, Inc.
BEDFORD, Mass. --(BUSINESS WIRE)--Oct. 16, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid ("HA") technology platform , today announced plans to showcase its
Industry veteran brings extensive experience leading global regulatory, quality, and clinical affairs teams BEDFORD, Mass. --(BUSINESS WIRE)--Oct. 14, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated company, focused on developing regenerative therapies leveraging its
BEDFORD, Mass. --(BUSINESS WIRE)--Oct. 10, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its third-quarter 2019 financial results after the close of the market on Thursday, October 24, 2019 and hold its investor conference call on the same day,
BEDFORD, Mass. --(BUSINESS WIRE)--Oct. 4, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated regenerative therapies company leveraging its proprietary hyaluronic acid ("HA") technology platform , today announced plans to showcase its osteoarthritis pain management and joint
BEDFORD, Mass. --(BUSINESS WIRE)--Sep. 18, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company leveraging its proprietary hyaluronic acid ("HA") technology platform to provide therapies across the Joint Preservation and Restoration continuum of care,
BEDFORD, Mass. --(BUSINESS WIRE)--Sep. 4, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that it will host an Analyst and Investor Day on
BEDFORD, Mass. --(BUSINESS WIRE)--Sep. 3, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that Joseph Darling , President and
